Cargando…

A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors

Phosphatidylinositol 3-kinase (PI3K) pathway activation is associated with resistance to paclitaxel in solid tumors. We assessed the safety and activity of alpelisib, an oral, selective PI3K p110α inhibitor, plus paclitaxel in patients with advanced solid tumors. This Phase Ib, multicenter, open-lab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodon, Jordi, Curigliano, Giuseppe, Delord, Jean-Pierre, Harb, Wael, Azaro, Analia, Han, Yu, Wilke, Celine, Donnet, Valerie, Sellami, Dalila, Beck, Thaddeus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114962/ https://www.ncbi.nlm.nih.gov/pubmed/30167089 http://dx.doi.org/10.18632/oncotarget.25854

Ejemplares similares

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours
por: Bono, Petri, et al.
Publicado: (2020)

A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies
por: Tsang, Erica S., et al.
Publicado: (2022)

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors
por: Beatty, Gregory L., et al.
Publicado: (2018)

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2019)

Unveiling changes in the landscape of patient populations in cancer early drug development
por: Hierro, Cinta, et al.
Publicado: (2016)

Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021)

Alpelisib for breast cancer
Publicado: (2022)

Alpelisib-Induced Diabetic Ketoacidosis
por: Espinosa, Luis Borges, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis
por: Nguyen, Paul, et al.
Publicado: (2021)

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors
por: Bauer, Todd M, et al.
Publicado: (2018)

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer
por: Kim, Kui-Jin, et al.
Publicado: (2020)

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
por: Wen, Patrick Yung, et al.
Publicado: (2020)

Ketoacidosis in a Patient with Type 2 Diabetes Requiring Alpelisib: Learnings and Observations Regarding Alpelisib Initiation and Rechallenge
por: Leung, Mova, et al.
Publicado: (2022)

Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors
por: Gordon, Michael S., et al.
Publicado: (2022)

A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
por: Shoushtari, Alexander N., et al.
Publicado: (2021)

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
por: Baird, Richard D., et al.
Publicado: (2021)

In Vitro Systematic Drug Testing Reveals Carboplatin, Paclitaxel, and Alpelisib as a Potential Novel Combination Treatment for Adult Granulosa Cell Tumors
por: Roze, Joline, et al.
Publicado: (2021)

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
por: Lee, Matilda Xinwei, et al.
Publicado: (2022)

Alpelisib-Induced Diabetic Ketoacidosis- A Case Report
por: Rodriguez, Lisette Patricia, et al.
Publicado: (2021)

A Case of Diabetic Keto Acidosis From Alpelisib
por: Thumma, Soumya P, et al.
Publicado: (2021)

Alpelisib-Induced Hyperglycemia- A Small Case Series
por: Ekanayake, Preethika Subashini, et al.
Publicado: (2021)

Case report: Alpelisib-induced Stevens–Johnson syndrome
por: Kurian, Christine Jane, et al.
Publicado: (2022)

Bilateral Panuveitis and Exudative Retinal Detachments Associated with Alpelisib
por: Chong, Yu Jeat, et al.
Publicado: (2022)

Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions
por: Schutte, Tim, et al.
Publicado: (2023)

Paclitaxel in vitro reversibly sensitizes the excitability of IB4(−) and IB4(+) sensory neurons from male and female rats
por: Villalba‐Riquelme, Eva, et al.
Publicado: (2022)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

Radium-223 in combination with paclitaxel in cancer patients with bone metastases: safety results from an open-label, multicenter phase Ib study
por: Geva, Ravit, et al.
Publicado: (2018)

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
por: Wesolowski, Robert, et al.
Publicado: (2019)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient
por: Fugere, Tyler, et al.
Publicado: (2021)

A multidisciplinary approach to optimizing care of patients treated with alpelisib
por: Rugo, Hope S., et al.
Publicado: (2021)

RF07 | PSUN359 Alpelisib-induced Diabetic Ketoacidosis
por: Majumdar, Sachin, et al.
Publicado: (2022)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
por: Rosenthal, Mark, et al.
Publicado: (2020)

A systematic review and meta-analysis of selected toxicity endpoints of alpelisib
por: Shields, Misty, et al.
Publicado: (2020)

Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature
por: Carrillo, Maritza, et al.
Publicado: (2020)

Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma
por: Xu, Hongwei, et al.
Publicado: (2021)

Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021)

Alpelisib-Induced Diabetes Mellitus: Case Report, Pharmacodynamics and Management Considerations
por: Pla Peris, Begoña, et al.
Publicado: (2022)

Alpelisib-Induced Diabetic Ketoacidosis in a Patient With Metastatic Breast Cancer
por: Abufaied, Mohamad, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_59en48qu730n05ftbqnv23ae1c